Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Finwise BancorpFINW · Entity 6350 | Director | March 31, 2026 | April 01, 2026 |
| MIRA PHARMACEUTICALS, INC.MIRA · Entity 7362 | Chief Financial Officer | May 15, 2025 | June 10, 2025 |
| Telomir Pharmaceuticals, Inc.TELO · Entity 6962 | Chief Financial Officer | May 15, 2025 | June 10, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Finwise Bancorp
Report date March 31, 2026 · Filed April 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | Direct | 59,242 |
Reported balance
After 2026-03-31 transaction · row 1
1 source rowRow 1 · 2026-03-31 · Grant · Acquired 3,179 · Balance 59,242 F1: The price reported in Column 4 is equal to the average closing price of the issuer's common stock for the fifteen trading days ending the day before the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is equal to the average closing price of the issuer's common stock for the fifteen trading days ending the day before the date of grant.
MIRA PHARMACEUTICALS, INC.
Report date May 15, 2025 · Filed June 10, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.18 · Expires 2035-05-13 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2025-05-15 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The stock options were issued to the Reporting Person on May 19, 2024 (the "Grant Date"), pursuant to the Issuer's 2023 Omnibus Incentive Plan (the "Plan"). Twenty-five thousand (37,500) of the options will vest six (6) months following May 19, 2025, and twenty-five thousand (37,500) of the Option will vest twelve (12) months following May 25, 2025, subject to Mr. Weichselbaum's continued employment by the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options were issued to the Reporting Person on May 19, 2024 (the "Grant Date"), pursuant to the Issuer's 2023 Omnibus Incentive Plan (the "Plan"). Twenty-five thousand (37,500) of the options will vest six (6) months following May 19, 2025, and twenty-five thousand (37,500) of the Option will vest twelve (12) months following May 25, 2025, subject to Mr. Weichselbaum's continued employment by the Issuer on each such vesting date.
Telomir Pharmaceuticals, Inc.
Report date May 15, 2025 · Filed June 10, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.75 · Expires 2035-05-13 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2025-05-15 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The stock options were issued to the Reporting Person on May 19, 2024 (the "Grant Date"), pursuant to the Issuer's 2023 Omnibus Incentive Plan (the "Plan"). Twenty-five thousand (25,000) of the options will vest six (6) months following May 14, 2025, and twenty-five thousand (25,000) of the option will vest twelve (12) months following May 13, 2025, subject to Mr. Weichselbaum's continued employment by the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options were issued to the Reporting Person on May 19, 2024 (the "Grant Date"), pursuant to the Issuer's 2023 Omnibus Incentive Plan (the "Plan"). Twenty-five thousand (25,000) of the options will vest six (6) months following May 14, 2025, and twenty-five thousand (25,000) of the option will vest twelve (12) months following May 13, 2025, subject to Mr. Weichselbaum's continued employment by the Issuer on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2026 Filed Apr 1, 2026 20:13 UTC | Finwise Bancorp FINW · Entity 6350 | GrantCommon Stock, par value $0.001 per share | 3,179 | $15.73 | $50,005.67 |
DisclosureSEC source: 0001856365-26-000023 · wk-form4_1775074428.xml · nonDerivative · entry 1 Weichselbaum Alan · CIK 0001435390 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,242 F1 · price: The price reported in Column 4 is equal to the average closing price of the issuer's common stock for the fifteen trading days ending the day before the date of grant. Read SEC document |
| May 27, 2025 Filed May 29, 2025 22:21 UTC | Finwise Bancorp FINW · Entity 6350 | GrantCommon Stock, par value $0.001 per share | 2,721 | $14.70 | $39,998.70 |
DisclosureSEC source: 0001435390-25-000002 · wk-form4_1748557277.xml · nonDerivative · entry 1 Weichselbaum Alan · CIK 0001435390 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,063 Read SEC document |
| May 28, 2024 Filed May 29, 2024 21:11 UTC | Finwise Bancorp FINW · Entity 6350 | GrantCommon Stock, par value $0.001 per share | 3,957 | $0.00 | $0.00 |
DisclosureSEC source: 0001435390-24-000002 · wk-form4_1717017067.xml · nonDerivative · entry 1 Weichselbaum Alan · CIK 0001435390 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,342 Read SEC document |
| April 18, 2023 Filed Apr 20, 2023 17:26 UTC | Finwise Bancorp FINW · Entity 6350 | GrantCommon Stock, par value $0.001 per share | 4,803 | $0.00 | $0.00 |
DisclosureSEC source: 0001435390-23-000002 · wf-form4_168201158756343.xml · nonDerivative · entry 1 Weichselbaum Alan · CIK 0001435390 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,385 Read SEC document |
| December 14, 2022 Filed Dec 16, 2022 21:16 UTC | Finwise Bancorp FINW · Entity 6350 | GrantCommon Stock, par value $0.001 per share | 1,082 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-045875 · form4.xml · nonDerivative · entry 1 Weichselbaum Alan · CIK 0001435390 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,582 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.